AGLE News

Just one week old, the 2Q has already seen one pricing, three launches, three initial filings and significant filings updates. This represents the most IPO-related activity since early in the 1Q. A familiar move from the biotech playbook Aeglea BioTherapeutics (AGLE), which is developing enzymes for rare genetic metabolic diseases and...read more

Aeglea BioTherapeutics, which is developing enzymes for rare genetic metabolic diseases and tumors, raised $50 million by offering 5 million shares at $10. It had originally planned to raise $60 million by offering 3.5 million shares at a range of $16 to $18. Aeglea BioTherapeutics plans to list on the Nasdaq under the symbol AGLE. UBS Investment Bank, BMO Capital Markets and...read more

•Another small-cap biotech is set to kick off Q2 pricings •Timing of the IPO window reopening is still uncertain, but the pipeline remains robust First IPO of the second quarter Aeglea Biotherapeutics (AGLE), which is developing enzymes for rare genetic metabolic diseases and tumors, is planning to price its $60 million IPO...read more

Aeglea BioTherapeutics, which is developing enzymes for rare genetic metabolic diseases and tumors, announced terms for its IPO on Monday. The Austin, TX-based company plans to raise $60 million by offering 3.5 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Aeglea BioTherapeutics would command a fully diluted market value of $203 million. ...read more